Assenagon Asset Management S.A. Reduces Position in Integra LifeSciences Holdings Corporation $IART

Key Points

• Assenagon Asset Management cut its Integra LifeSciences stake by 66.3% in the second quarter, selling 276,774 shares and retaining 140,633 shares worth approximately $2.5 million. Institutional investors collectively own 84.78% of IART.
• Analyst sentiment remains cautious: the stock has an average “Reduce” rating and a consensus price target of $18.86, despite Argus upgrading it to “Buy” with a $25 target.
• Integra reported quarterly EPS of $0.56, exceeding estimates of $0.48, on revenue of $418.76 million. Shares opened at $18.24, up 4.9%, while the company guided for fiscal 2026 EPS of $2.40–$2.50.

Assenagon Asset Management S.A. trimmed its stake in Integra LifeSciences Holdings Corporation (NASDAQ:IART - Free Report) by 66.3% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 140,633 shares of the life sciences company's stock after selling 276,774 shares during the quarter. Assenagon Asset Management S.A. owned approximately 0.18% of Integra LifeSciences worth $2,526,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Rubric Capital Management LP boosted its stake in shares of Integra LifeSciences by 58.4% during the 2nd quarter. Rubric Capital Management LP now owns 7,353,934 shares of the life sciences company's stock worth $90,233,000 after purchasing an additional 2,710,262 shares during the last quarter. Paradigm Capital Management Inc. NY raised its position in shares of Integra LifeSciences by 50.6% in the first quarter. Paradigm Capital Management Inc. NY now owns 4,012,698 shares of the life sciences company's stock valued at $37,800,000 after buying an additional 1,347,700 shares during the last quarter. Bank of America Corp DE raised its position in shares of Integra LifeSciences by 71.4% in the first quarter. Bank of America Corp DE now owns 1,414,509 shares of the life sciences company's stock valued at $13,325,000 after buying an additional 589,408 shares during the last quarter. Invenomic Capital Management LP lifted its stake in shares of Integra LifeSciences by 78.3% during the fourth quarter. Invenomic Capital Management LP now owns 1,055,941 shares of the life sciences company's stock valued at $13,115,000 after buying an additional 463,729 shares during the period. Finally, Kotler Kevin purchased a new position in shares of Integra LifeSciences during the fourth quarter valued at approximately $5,309,000. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have commented on IART. Citigroup reaffirmed a "neutral" rating and issued a $19.00 target price (up from $16.00) on shares of Integra LifeSciences in a research note on Wednesday, July 8th. Wells Fargo & Company increased their price target on Integra LifeSciences from $15.00 to $18.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 30th. Wall Street Zen cut Integra LifeSciences from a "strong-buy" rating to a "buy" rating in a report on Saturday, July 18th. UBS Group started coverage on Integra LifeSciences in a research report on Tuesday, July 28th. They issued a "neutral" rating and a $19.00 price objective for the company. Finally, Argus upgraded Integra LifeSciences from a "hold" rating to a "buy" rating and set a $25.00 target price for the company in a research note on Thursday, June 18th. One investment analyst has rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Reduce" and a consensus target price of $18.86.

Integra LifeSciences Stock Up 4.9%

Shares of NASDAQ IART opened at $18.24 on Friday. Integra LifeSciences Holdings Corporation has a 52-week low of $8.70 and a 52-week high of $20.49. The firm has a fifty day moving average of $18.00 and a 200-day moving average of $13.81. The stock has a market capitalization of $1.42 billion, a PE ratio of -202.64, a P/E/G ratio of 1.47 and a beta of 1.21. The company has a quick ratio of 2.11, a current ratio of 3.60 and a debt-to-equity ratio of 1.75.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its earnings results on Wednesday, July 29th. The life sciences company reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.08. The business had revenue of $418.76 million for the quarter, compared to analyst estimates of $417.54 million. Integra LifeSciences had a positive return on equity of 18.30% and a negative net margin of 0.44%.Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. On average, analysts anticipate that Integra LifeSciences Holdings Corporation will post 2.46 EPS for the current year.

Integra LifeSciences Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source